Evidence map›Paper›PMID 35163509›Full record

ReviewInternational journal of molecular sciences2022

Update on Novel Targeted Therapy for Pleural Organization and Fibrosis.

Torry A Tucker, Steven Idell

Open access · goldAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Pleural Fibrosis: Now That's What mTORC(ing) About.American journal of respiratory cell and molecular biology · 2024
    Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Torry A TuckerThe Department of Cellular and Molecular Biology, The University of Texas Health Science Center at Tyler, 11937 US Hwy 271, Tyler, TX 75708, USA.
Steven IdellThe Department of Cellular and Molecular Biology, The University of Texas Health Science Center at Tyler, 11937 US Hwy 271, Tyler, TX 75708, USA.ORCID 0000-0003-4389-2152
The University of Texas Health Science Center at Tyler · US

Funding

Myocardin in the pathogenesis of pleural remodelingR01HL142853 · NHLBI · UNIVERSITY OF TEXAS HLTH CTR AT TYLER · PI IDELL, STEVEN, IKEBE, MITSUO · 2019 to 2022
$1.9M
Fibrinolytic Proteases, meso-mesenchymal transition and pleural remodelingR01HL130133 · NHLBI · UNIVERSITY OF TEXAS HLTH CTR AT TYLER · PI TUCKER, TORRY ALLE · 2017 to 2021
$1.8M
NHLBI NIH HHS R01 HL130133NHLBI NIH HHS R01 HL142853
6 · The paper itself

Abstract

Pleural injury and subsequent loculation is characterized by acute injury, sustained inflammation and, when severe, pathologic tissue reorganization. While fibrin deposition is a normal part of the injury response, disordered fibrin turnover can promote pleural loculation and, when unresolved, fibrosis of the affected area. Within this review, we present a brief discussion of the current IPFT therapies, including scuPA, for the treatment of pathologic fibrin deposition and empyema. We also discuss endogenously expressed PAI-1 and how it may affect the efficacy of IPFT therapies. We further delineate the role of pleural mesothelial cells in the progression of pleural injury and subsequent pleural remodeling resulting from matrix deposition. We also describe how pleural mesothelial cells promote pleural fibrosis as myofibroblasts via mesomesenchymal transition. Finally, we discuss novel therapeutic targets which focus on blocking and/or reversing the myofibroblast differentiation of pleural mesothelial cells for the treatment of pleural fibrosis.

Indexed as

AnimalsDisease ProgressionDrug Delivery SystemsFibrosisGene Expression RegulationHumansPlasminogen Activator Inhibitor 1PleuraRecombinant ProteinsUrokinase-Type Plasminogen ActivatorPlasminogen Activator Inhibitor 1Recombinant ProteinssaruplaseSERPINE1 protein, humanUrokinase-Type Plasminogen Activatorfibrinous neomatricesintrapleural fibrinolytic therapy (IPFT)mesomesenchymal transition (MesoMT)organization and scarificationpleural injurypleural loculation and fibrothoraxpleural mesothelial cells

Identifiers

PMID35163509
PMCPMC8835949
OpenAlexW4210352578

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.